Get the Stockscreener App
3.20
1.27%
0.04
After Hours:
3.20
Neuphoria Therapeutics Inc stock is traded at $3.20, with a volume of 18,246.
It is up +1.27% in the last 24 hours and up +0.00% over the past month.
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
See More
Previous Close:
$3.16
Open:
$3.15
24h Volume:
18,246
Relative Volume:
1.95
Market Cap:
$11.25B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.36%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.07
$3.30
1-Week Range:
$3.04
$3.60
52-Week Range:
$2.90
$3.9441
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
61 8 8150 7400
Address
200 GREENHILL ROAD, EASTWOOD SA
Compare NEUP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.20 | 11.25B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.66 | 106.01B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.87 | 75.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.60 | 39.80B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.51 | 31.02B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.43 | 26.95B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder - Marketscreener.com
Bionomics Limited Publishes the Positive Results from the Phase 2 June Study of Bnc210 in Patients with Post-Traumatic Stress Disorder in Nejm Evidence - Marketscreener.com
Bionomics Limited announced that it expects to receive $70 million in funding - Marketscreener.com
Bionomics Limited to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Marketscreener.com
Bionomics Limited Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder - Marketscreener.com
NEUP (Neuphoria Therapeutics) Cash From Other Investing Act - GuruFocus.com
NEUP (Neuphoria Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
We're Keeping An Eye On Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Rate - Yahoo Finance
Bionomics Strategic Shift with Neuphoria Redomiciliation - Yahoo Finance
Neuphoria Therapeutics More Than Doubles After Bionomics Re-Domiciliation - MarketWatch
Big Moves in Biotech! Neuphoria's Bold Transformation Unveiled! - Jomfruland.net
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - GlobeNewswire
Bionomics Secures Major Court Approval for Strategic US Market Shift, Sets December Trading Timeline - StockTitan
Results of Scheme Meeting - The Manila Times
Bionomics Secures 96% Shareholder Approval for US Re-domiciliation, Plans Nasdaq Listing as Neuphoria - StockTitan
Bionomics Limited (BNOX) Quarterly 10-Q Report - Quartz
Bionomics : Scheme Implementation Agreement – Amending Agreement Form 8 K - Marketscreener.com
Bionomics CEO believes company has ‘significant, unrealized value’ - Yahoo Finance
Apeiron entities sell Bionomics shares worth $82,526 - Investing.com
Bionomics Limited announces intention to re-domicile to the United States - GlobeNewswire
Bionomics Initiates Affirm-1, A Phase 3 Clinical Trial with Bnc210 for Social Anxiety Disorder - Marketscreener.com
Bionomics to Present at Biotech Showcase™ 2024 - Marketscreener.com
Biometrics Soar After Company Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms - Marketscreener.com
BNOXBionomics Limited American Depository Shares Latest Stock News & Market Updates - StockTitan
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
There is no financial data for Neuphoria Therapeutics Inc (NEUP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.13%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):